Orencia® (abatacept) 125mg solution for injection - New Formulation

Source: eMC (electronic Medicines Compendium) Area: Other Library Updates > SPC Changes Bristol-Myers Squibb has been granted marketing authorisation for a new formulation given by subcutaneous injection.   Orencia® (abatacept) in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs including methotrexate or a tumour necrosis factor-alpha inhibitor.   Please see link to SPC for full prescribing information.
Source: NeLM - SPC Changes - Category: Drugs & Pharmacology Source Type: news